The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease

Disease Management

Volumn 10, Issue 1, 2007, Pages 37-45

  Lefebvre, Patrick ^a   Duh, Mei Sheng ^b   Mody, Samir H ^c   Bookhart, Brahim ^c   Piech, Catherine Tak ^c  

^a GROUPE D ANALYSE   (Canada)

^b ANALYSIS GROUP   (United States)

^c Ortho Biotech Products LP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; COST CONTROL; DISEASE COURSE; ELDERLY CARE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE PLANNING; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; RENAL REPLACEMENT THERAPY; THERAPY DELAY;

AGED; COMORBIDITY; COST SAVINGS; DISEASE PROGRESSION; EPOETIN ALFA; GLOMERULAR FILTRATION RATE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MEDICARE; MODELS, ECONOMIC; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 33847624113     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.2006.626     Document Type: Article

References (21)

1. U.S. Renal Data System. USRDS 2005 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2005. Available at: www.usrds.org/reference.htm. Accessed December 1, 2006.
2. Penninx B, Pahor M, Cesari M, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 2004;52:719-724.
3. Dharmarajan TS, Norkus EA. Mild anemia and the risk of falls in older adults from nursing homes and the community. J Am Med Dir Assoc 2004;5:395-400.
4. Woodman RC, Yektashenas BH, Fu M, et al. Anemia in two groups of elderly (65-79 and ≥80) patients with chronic kidney disease (CKD). Blood 2004;104:15b (abst).
5. PROCRIT® (epoetin alfa) prescribing information. Raritan, NJ: Ortho Biotech Products, L.P., 2006.
6. Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004;60:392-405.
7. Revicki DA, Brown RE, Feeny DH, et al. Health-related qualify of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-554.
8. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18:ii2-ii6.
9. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002;40:1153-1161.
10. St Peter WL, Xue JL, Ebben JP, et al. Pre-ESRD erythropoietin use predicts Medicare expenditures in periods before and after end-stage renal disease diagnosis. J Am Soc Nephrol 2001;12:247A(abst).
11. Dean BB, Dylan M, Gano A Jr, Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005;21:981-987.
12. Gouva C, Nikolopoulos P, Ioannidis JPA, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 2004;66:753-760.
13. Jungers P, Choukrun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307-312.
14. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77:176-185.
15. Paoletti E, Cannella G. Update on erythropoietin treatment: should hemoglobin be normalized in patients with chronic kidney disease? J Am Soc Nephrol 2006;7:S74-S77.
16. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266.
19. U.S. Department of Labor, Bureau of Labor Statistics. Consumer price index for medical care services, 1996-2005. Available at: http://data.bls.gov/ PDQ/servlet/SurveyOutputServlet;jsessionid=f030c0537e a0$3F$ 2D$1. Accessed December 1, 2006.
20. Trivedi HS, Pang MMH, Campbell A, Saads P. Slowing the progression of chronic renal failure: economic benefits and patients' perspectives. Am J Kidney Dis 2002;39:721-729.
21. U.S. Census Bureau. Current population survey. Racial statistics branch. Available at: www.census, gov/population/socdemo/race/black/ppl-164/tab11.pdf. Accessed December 1, 2006.